Piramal Pharma Solutions Partners with Botanix for Sofdra Development

Piramal Pharma Solutions (PPS) has announced a strategic partnership with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, for the development and commercial supply of Sofdra®. Sofdra is a newly FDA-approved chemical entity targeting primary axillary hyperhidrosis. The collaboration leverages PPS's North American facilities to ensure consistent patient access to the drug.

Under this partnership, PPS will commence development and validation services for the active pharmaceutical ingredient in Sofdra at its Michigan facility. Following this, the process may also be validated at PPS’s Aurora, Canada site, providing Botanix with dual-source commercial API supply options. This strategic move aims to enhance supply chain security and flexibility.

PPS boasts extensive expertise in drug development, with both its Riverview and Aurora facilities equipped for efficient, cost-effective production. The twin-site strategy is designed to mitigate risks and maintain supply chain continuity. This adaptability ensures ongoing supply for Botanix amid potential global uncertainties.